Bone Therapeutics’ ALLOB Achieves Primary Endpoint in Delayed-Union Fracture Study

Bone Therapeutics reported that all patients enrolled in the Phase I/IIA study of ALLOB® allogeneic bone cell therapy met the primary endpoint of statistically significant clinical and radiological improvements in the treatment of delayed-union fractures.

At six months following one percutaneous dose of ALLOB to the fracture site, the 21...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us